To hear about similar clinical trials, please enter your email below
Trial Title:
PET-MRI Esophagus Feasibility Study
NCT ID:
NCT05796102
Condition:
Esophagogastric Cancer
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Health Services Research
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
PET-MRI
Description:
A PET/MRI scan is a two-in-one test that combines images from a positron emission
tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance
Imaging (MRI) provides better soft tissue contrast compared to conventional computerized
tomography (CT), and when combined with PET, can potentially provide better visualization
of the tumor shape, size, and position.
Additional MRI imaging will be completed once during radiation treatment, and once after
radiation treatment
Arm group label:
PET-MRI
Summary:
This is a single arm, single centre, investigator initiated study to investigate the
feasibility of using PET-MRI imaging in radiation treatment workflow in up to 15 patients
with esophagogastric cancer. PET-MRI imaging will be completed before the start of
radiation treatment. MRI imaging will be completed during radiation treatment and after
radiation treatment. These images will not be used to plan the radiation treatment and
routine clinical care will be provided.
The goal of this study is to gather information that will allow the radiation team to
include MRI and PET imaging into the radiation treatment workflow for patients with
esophageal cancer receiving radiation therapy in the future.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients 18 years or older
- Diagnosed with locally advanced esophageal cancer being considered for conventional
RT >4 weeks
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Contraindication for MRI
- Contraindication for Gadolinium (i.e. inability to lie supine for at least 60
minutes)
- Any patient who is pregnant or breastfeeding
- Pacemaker or implanted defibrillator
- Claustrophobia
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Princess Margaret Cancer Centre
Address:
City:
Toronto
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Melissa Bartolo Rego
Email:
rmp.regulatory.affairs@rmp.uhn.ca
Start date:
March 28, 2023
Completion date:
May 2026
Lead sponsor:
Agency:
University Health Network, Toronto
Agency class:
Other
Source:
University Health Network, Toronto
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05796102
